Arca
Skip to content
Tools
Tools

EDNRB: Endothelin receptor type B

Non-specific receptor for endothelin 1, 2, and 3.

  • Drugs that act on it: 4
  • Approved: 0
  • In phases 1 to 3: 4
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on EDNRB, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3
  • Other 1

Approved0

    Phase 32

    • Tezosentan
    • Darusentan

    Phase 21

    • Enrasentan

    Phase 11

    • RG-7636

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Endothelin receptor ET-B antagonist; the rest name their own mechanism.
    TezosentanPhase 3Liquidia TechnologiesSmall moleculeAntagonist31
    DarusentanPhase 3Gilead SciencesSmall moleculeAntagonist0
    EnrasentanPhase 2—Small moleculeAntagonist0
    RG-7636Phase 1—OtherBinding agentEndothelin receptor ET-B binding agent0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
    Colchicine in Pulmonary Artery Hypertension PatientsTezosentanPhase 2Not yet recruitingAin Shams UniversityOct 30, 2026
    PACE: Prostacyclin AntiCoagulation in ECMOTezosentanPhase 1 / Phase 2Not yet recruitingGarrett KeimSep 24, 2026
    A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral SelexipagTezosentanPhase 4RecruitingLiquidia Technologies, Inc.Aug 12, 2026
    A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon AttacksTezosentanPhase 2Not yet recruitingLiquidia Technologies, Inc.Aug 5, 2026
    Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial HypertensionTezosentanPhase 4RecruitingUniversity of Sao Paulo General HospitalJul 20, 2026
    Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)TezosentanNot applicableNot yet recruitingUniversity of AlbertaJul 14, 2026
    A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)TezosentanPhase 4RecruitingMerck Sharp & Dohme LLCMay 22, 2026
    Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial HypertensionTezosentan—Not yet recruitingCaio Júlio César dos Santos FernandesMar 5, 2026

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Waardenburg syndrome type 4A0.78
    • Waardenburg-Shah syndrome0.69
    • ABCD syndrome0.65
    • Hypertensive disorder0.58
    • Hirschsprung disease0.58
    • Abnormality of the skeletal system0.51
    • Waardenburg syndrome0.50
    • Congenital heart disease0.46
    • Hair color0.45

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1785, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P24530, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.